Curi Bio provides seamless, bioengineered integration of human cells, systems, and data to accelerate the discovery of new medicines. Curi’s suite of human stem cell-based products and services enable scientists to build mature and predictive human iPSC-derived tissues, with a focus on cardiac, musculoskeletal, and neuromuscular models for discovery, safety testing, and efficacy testing of new therapeutics.
By offering drug developers an integrated platform comprising highly predictive human iPSC-derived cells and tissues and clinically-relevant data, Curi aims to dramatically accelerate the discovery and development of safer, more effective medicines.
Total Funding: $16 M
Funding Stage: Series A
Business Stage: Scaling Up
Market: B2B
Company Size: 26 to 50
Founded: 2015
For AI/ML Startup Founders
Get introduced to VC/PE/CVC investors
For Investors at VC/PE firms
Get introduced to AI/ML Startup founders or founders at Curi Bio
Principal Electrical Engineer
Seattle, WA
Cardiac Stem Cell Scientist (PhD Level)
Seattle, WA